Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for 90%--95% of all diabetic patients, which is primarily due to the relative lack of insulin secretion or reduced sensitivity to insulin \[[@CR1], [@CR2]\]. According to the latest report, the worldwide prevalence of adult diabetes has reached 9.3%, equivalent to 463 million adults worldwide with diabetes \[[@CR3]\]. T2DM has become a serious global public health problem. Therefore, it is of practical significance to develop new drugs for the treatment of T2DM.

Traditional Chinese medicine (TCM) has been widely used in health care in many Asian countries for thousands of years. With the release of the detailed description of TCM by the 11th version of the International Statistical Classification of Diseases and Related Health Problems (ICD), TCM is more widely and gradually accepted around the world. Zengye decoction (ZYD) is a well-known TCM prescription used to treat 'wasting thirst syndrome', which would probably be diagnosed as T2DM according to the nationwide unified western medicine diagnostic criteria \[[@CR4], [@CR5]\]. ZYD was initially recorded in *wen bing tiao bian* written by Wu tang in Qing Dynasty of Chinese history (1936 AD-1912 AD) and is composed of *Scrophulariae Radix*, *Rehmanniae Radix* and *Ophiopogonis Radix*. Modern pharmacological studies show that ZYD exhibits hypoglycemic effect \[[@CR6], [@CR7]\]. However, the mechanism corresponding to its hypoglycemic effect is still unclear, due to the sophisticated features of multi-components and biological multi-effect of TCM \[[@CR8]\]. Therefore, it is necessary to evaluate the therapeutic substances of hypoglycemic effect using modern scientific research methods, not only the herbal phytochemical compositions but also the absorption and metabolism of active ingredients in vivo of T2DM.

There have been some researches on the chemical constituents and herbal ingredients of ZYD in previous studies \[[@CR9], [@CR10]\]. A few reports have studied the absorption of a few compounds of ZYD \[[@CR11]\]. We have demonstrated that ZYD improves insulin resistance in T2DM rats \[[@CR12]\]. However, the metabolism of ZYD in experimental diabetes models has not reported. Actually, in the pathological state of diabetes, the absorption, distribution, metabolism, and excretion of ZYD may be different from those in the natural and healthy state \[[@CR13], [@CR14]\]. This ambiguity presents the greatest obstacle to deeper pharmacological mechanism investigation and scientific connotation interpretation. Therefore, a comprehensive, systematic analysis of the absorption and metabolic components of ZYD in vivo under the diabetic state is urgent.

In this paper, a rapid procedure using high-performance liquid chromatography coupled with electrospray ionization quadrupole time of flight tandem mass spectrometry (HPLC-ESI-Q-TOF--MS/MS) was established to characterize complex chemical compounds and metabolic components. In actual, HPLC-ESI-Q-TOF--MS/MS has been substantially applied to qualitative analysis of multiple components and metabolites in the complex mixture especially for the TCM prescriptions owing to its extraordinary performance, high resolution, accurate mass measurement, and rapid scan speed \[[@CR15]\]. In the present study, a rat model of T2DM was established, and the absorbed components and metabolic ingredients in plasma, bile, urine, feces were screened after oral administration of ZYD. At the same time, the proposed fragmentation pathways and possible metabolic behaviors of the composition of ZYD in vivo were described in detail.

Methods {#Sec2}
=======

Chemicals and reagents {#Sec3}
----------------------

HPLC-grade acetonitrile was purchased from Tedia (Fairfield, OH, USA). HPLC-grade methanol was purchased from CINC High Purity Solvents Co. Ltd (Shanghai, China). The purified water was obtained using a Milli-Q water purification system (Millipore, Bedford, MA, USA). Formic acid of HPLC-grade was purchased from Aladdin Bio-Chem Technology Co. Ltd (Shanghai, China). *n*-Butanol was purchased from Sinopharm Chemical Reagent Co. Ltd (Nanjing, China). Catalpol, leonuride, acteoside, isoacteoside, harpagide, harpagoside, were obtained from Sichuan Weikeqi biological technology Co., Ltd (purity ≥ 98%). Cinnamic acid, *p*-coumaric acid, ferulic acid, were obtained from Chengdu Biopurify Phytochemicals Ltd (purity ≥ 98%). Streptozotocin (STZ) was purchased from Sigma (St. Louis, MO, USA). All other chemicals and solvents were of analytical grade.

Preparation of Zengye decoction extract {#Sec4}
---------------------------------------

The crude drugs of *Scrophulariae Radix*, dried *Rehmanniae Radix*, *Ophiopogonis Radix* were purchased from Nanjing Traditional Chinese Medicine Clinics (Nanjing, China). The three herbs were authenticated by professor Jin Qi (Jiangsu Key Laboratory of TCM Evaluation and Translational Research). The crude drugs (130 g. *Scrophulariae Radix*: dried *Rehmanniae Radix*: *Ophiopogonis Radix*, 5:4:4, w/w/w) were soaked in double-distilled water and extracted three times by boiling in distilled water (1300 mL, 1040 mL, 780 mL) under reflux for 1 h. And then, the collected filtrates were combined, concentrated, and freeze-dried to obtain a lyophilized powder.

Preparation model of T2DM rats and drug administration {#Sec5}
------------------------------------------------------

Male Wistar rats weighing 140--160 g were purchased from Comparative Medicine Center of Yangzhou University (Yangzhou, China). The rats were raised in an air-conditioned room at 23 ± 1 °C and a 12 h light/dark cycle. The animals were adaptively fed for 1 week prior to use. All the operations were allowed by the Animal Ethics Committee of China Pharmaceutical University, China Pharmaceutical University, Nanjing, Jiangsu, China.

The model of T2DM rats was induced by high-fat diet combined with low-dose STZ (35 mg/kg) \[[@CR16]\]. The method was improved according to the previous reports and laboratory studies \[[@CR10], [@CR17]\]. Briefly, the animals were fed a high-fat diet for 3 weeks followed by intraperitoneal injection of STZ (35 mg/kg) which dissolved in cold citrate buffer (pH 4.3, 0.05 M). The fasting blood glucose (FBG) of rats was measured 3 days after injection, the level was higher than 11.1 mmol/L for subsequent experiments.

The T2DM rats were randomly divided into two groups. One group received ZYD (13 g/kg body weight, twice a day) via oral administration for 7 days. The other group received water, as the model control group. In addition, a normal healthy rats group received water, as the normal control group. The rats were fasted but with free access to water for 12 h before experiment.

Samples collection and pretreatment {#Sec6}
-----------------------------------

All samples were obtained after drug administration. The blood samples (n = 4) were collected from T2DM rats in the heparinized centrifugal tube at 0.5 h, 1 h, 2 h, 4 h and 8 h by retro-orbital venipuncture and immediately centrifuged at 1200×*g* for 15 min to obtain plasma. The urine and feces (n = 4) were collected at 0--24 h in independent metabolic cages. The feces samples were naturally dried in the fume hood and then crushed into powder. The bile (n = 4) was collected at 0--8 h by bile duct intubation and drainage under general anesthesia induced by 1% pentobarbital sodium, 55 mg/kg. All biological samples of the same type in the same group at each time point were equally combined into one sample, and stored at − 80 °C before pretreatment and analysis.

An aliquot of 1 mL plasma sample was added into triple volume of acetonitrile and vigorously vortexed for 1 min. Then the mixture was centrifuged at 1500 xg for 15 min. The supernatant was transferred to another centrifuge tube and evaporated to dryness under a gentle stream of nitrogen at 37 °C. The residual was reconstituted in 200 μL methanol: water mixture (7:3, v/v) and then centrifuged at 13,700×*g* for 15 min. The supernatant was filtered through 0.22 μm nylon microporous filter membrane. The filtrates were analyzed by HPLC-ESI-Q-TOF--MS/MS.

Likewise, an aliquot of 1 mL urine sample was added into 3 mL methanol and vortexed for 1 min. A weight of 0.8 g feces was extracted within 8 mL methanol for 30 min under ultrasonic. Afterwards, the mixture was centrifuged at 13,700×*g* for 15 min. The supernatant was transferred to another centrifuge tube and evaporated to dryness under a gentle stream of nitrogen at 37 °C. The residual was re-dissolved in 200 μL reconstituted solvent (methanol: water, 7:3, v/v) and centrifuged at 13,700×*g* for 15 min, and the solution was filtered through 0.22 μm nylon microporous filter membrane. The bile was pretreatment in the same way as urine.

HPLC-ESI-Q-TOF--MS/MS condition {#Sec7}
-------------------------------

Chromatographic separation was performed on an Agilent 1260 Infinity HPLC system (Agilent Technologies, Santa Clara, CA, USA) using a Diamonsil C18 column (4.6 × 250 mm, 5 μm) and a precolumn with the same packing at 30 °C. The mobile phase A was water containing 0.01% formic acid and phase B was acetonitrile containing 0.01% formic acid. The gradient elution conditions were as follows: 2% B at 0--10 min; 2--7% B at 10--20 min; 7--16% B at 20--45 min; 16--22% B at 45--60 min; 22--34% B at 60--85 min; 34--80% B at 85--115 min; 80--100% B at 115--125 min. The total flow rate was 1 mL/min, and an aliquot of 20 μL injected for analysis.

Mass spectrometry data were obtained using an Agilent 6530 Q-TOF MS/MS system (Agilent Technologies, Santa Clara, CA, USA) equipped with an ESI interface. The optimum parameters were set as follows: ESI source in the negative mode; drying gas (N~2~) flow rate 10.0 L/min; drying gas temperature 320 °C; nebulizer pressure 35 psi; capillary voltage 3500 V; skimmer 65 V; fragmentor voltage 120 V; MS/MS collision energy 25 V; scan range 100--2000 Da.

The HPLC-ESI-Q-TOF--MS/MS data were acquired and analyzed by an Agilent MassHunter Workstation Qualitative Analysis software version B.07.00 and PCDL manager B.07.00 (Agilent Technologies, Santa Clara, CA, USA).

Results {#Sec8}
=======

Identification of chemical profile of Zengye Decoction {#Sec9}
------------------------------------------------------

In order to more accurately characterize the intracorporal process of ZYD in the T2DM rats, the chemical constituents of ZYD were initially identified by HPLC-ESI-Q-TOF--MS/MS. In the present study, 80 compounds from ZYD were tentatively identified by comparing with the reference standards, the retention time, and reviewing literature \[[@CR9], [@CR10], [@CR19]--[@CR25]\]. The total ion chromatogram (TIC) of ZYD in negative mode was showed in Fig. [1](#Fig1){ref-type="fig"}a, and the detailed compounds information was summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Thirty-one previously undetected compounds were found compared with previous reports \[[@CR9], [@CR10]\]. In addition, the structural types of all compounds in ZYD were mainly iridoid glycosides, phenethylalchohol glycosides and phenylpropanoid glycosides, aromatic acid, homoisoflavonoids, steroidal saponins.Fig. 1**a** Total ion chromatogram (TIC) of Zengye decoction (ZYD) in the negative ion mode and **b**--**e** extracted ion chromatograms (EICs) of ZYD in biological and blank samples in the negative ion mode. **b**-1 ZYD plasma sample and **b**-2 blank plasma sample; **c**-1 ZYD bile sample and **c**-2 blank bile sample; **d**-1 ZYD urine sample and **d**-2 blank urine sample; and **e**-1 ZYD feces sample and **e**-2 blank feces sample

Characterization of ZYD prototype components absorbed in T2DM rats {#Sec10}
------------------------------------------------------------------

In this study, the biological samples, including plasma, urine, feces, and bile of T2DM rats treated with ZYD, were analyzed by HPLC-ESI-Q-TOF--MS/MS under constant conditions. Peaks which displayed at the same position on the chromatograms of both drug-containing biological samples and ZYD, but not in controlled blank biological samples were considered as absorbed and metabolic components of ZYD. Both TIC and EIC (extracted ion chromatograms) profiles were used to screen the absorbed prototype components. Finally, 11 compounds were observed in plasma, 17 were in urine, 5 were in bile, 35 were in feces in T2DM rats treated with ZYD. The EICs were showed in Fig. [1](#Fig1){ref-type="fig"}b1--e2 and the prototype compounds were listed in Table [1](#Tab1){ref-type="table"}. Furthermore, rehmapicrogenin was chosen as a representative absorbed component to demonstrate EICs further in Fig. [2](#Fig2){ref-type="fig"}. In contrast to the controlled blank biological samples, rehmapicrogenin showed remarkable peaks in drug-containing groups.Table 1Characterization of ZYD prototype components in vivo by HPLC-ESI-Q-TOF-MS/MSPeak No.t~R~(min)Precursor ions (*m/z*)FormulaError (mDa)Fragment ionsIdentificationPUFBRefs.ExperimentalTheoreticalP110.332407.1282\*407.1195C~17~H~22~O~10~− 8.70361.1038, 199.0607, 181.0507, 169.0505Catalpol+++−\[[@CR10]\]P220.658391.1284\*391.1246C~15~H~22~O~19~− 3.81211.1011, 183.0662, 165.0543, 139.0410Aucubin+++−\[[@CR10]\]P423.285731.2325\*731.2251C~27~H~42~O~20~− 7.35685.2276, 505.1599, 341.1118, 179.0561Rehmannioside D−++−\[[@CR10]\]P525.065409.1384\*409.1351C~15~H~24~O~10~− 3.05201.0771, 183.0663, 165.0556, 157.0504Harpagide++++\[[@CR10]\]P626.149393.1443\*393.1402C~15~H~24~O~9~− 4.06185.0560, 179.0526, 167.0716, 113.0238Leonuride++++\[[@CR10]\]P829.733373.1216373.1140C~16~H~22~O~10~− 7.58331.0989, 221.0893, 167.0426, 149.0622Geniposidic acid−++−\[[@CR18]\]P930.113421.1332\*421.1351C~16~H~24~O~10~1.95213.0732, 195.0662, 183.0657, 169.04376-*O*-methylcatalpol++++\[[@CR19]\]P1030.783461.1698461.1664C~20~H~30~O~12~− 3.35461.1698Decaffeoylacteoside−−+−\[[@CR10]\]P1131.790375.1317375.1297C~16~H~24~O~10~2.03375.13178-epilogonic acid−++−\[[@CR9]\]P1236.172487.1527487.1457C~21~H~28~O~13~− 6.99487.1527Cistanoside F−−+−\[[@CR10]\]P1441.765313.0938313.0929C~14~H~18~O~8~− 0.91313.0938, 229.1749, 137.0605, 123.0439Rhamnopyranosyl vanilloyl−+−−\[[@CR20]\]P1542.066475.1845475.1821C~21~H~32~O~12~− 2.4475.1845Darendoside B−−+−\[[@CR10]\]P1643.203607.2290607.2244C~26~H~40~O~16~− 4.64607.2298, 475.1859, 461.1697, 443.1586, 149.0457, 131.0351β-(3-hydroxy-4-methoxyhenyl) ethyl-*O*-α-L-arabinopyranosyl-(1 → 6)-*O*-\[6-α-L-rhamnpyranosyl-(1 → 3)-β-D-glucopyranoside−++−\[[@CR10]\]P2049.444183.1028183.1027C~10~H~16~O~3~− 0.13183.1036, 139.1123, 123.0792Rehmapicrogenin++++\[[@CR10]\]P2354.309435.2269\*435.2236C~19~H~34~O~8~− 3.33389.2370, 179.0539, 161.0451, 119.0348Rehmaionoside A/B−++−\[[@CR10]\]P2656.018799.2778799.2666C~36~H~48~O~20~− 11.18799.2778Jionoside A1/A2−++−\[[@CR21]\]P2456.295163.0399163.0401C~9~H~8~O~3~0.17145.0270, 119.0499*p*-coumaric acid+++−\[[@CR10]\]P2960.152193.0511193.0500C~10~H~10~O~4~− 0.47178.0269, 149.0598, 134.0369, 121,0282Ferulic acid−++−\[[@CR10]\]P3161.894623.2049623.1981C~29~H~36~O~15~− 6.76461.1676, 315.1084, 161.0241, 135.0445Acteoside−−+−\[[@CR10]\]P3463.221769.2634769.2561C~35~H~46~O~19~− 7.35769.2634Scrophuloside B1/B2−−+−\[[@CR22]\]P3663.473623.2021623.1981C~29~H~36~O~15~− 3.96623.2021Isoacteoside or Forsythoside A−−+−\[[@CR10]\]P3765.538525.1665525.1614C~24~H~30~O~13~− 5.14525.16658-*O*-caffeoyl harpagide−−+−\[[@CR19]\]P3967.938429.2171429.2130C~21~H~34~O~9~− 4.09249.1512, 231.1370, 187.1472Jiocarotenoside A1/A2−++−\[[@CR23]\]P4169.475783.2798783.2717C~36~H~48~O~19~− 8.10607.2294, 589.2154, 461.1666, 193.0500Angoroside C+−+−\[[@CR10]\]P4270.273783.2840783.2717C~36~H~48~O~19~− 12.30783.2840, 829.4135Isoangoroside C+−+−\[[@CR10]\]P4770.428637.2199637.2138C~30~H~38~O~15~− 6.11461.1706, 193.0512, 149.0577, 134.0372Leucosceptoside A−−+−\[[@CR21]\]P5275.561651.2397651.2294C~31~H~40~O~15~− 10.26651.2397Cistanoside D−−+−\[[@CR24]\]P5579.343539.1823\*539.1770C~24~H~30~O~11~− 5.29493.1715, 345.1210, 183.0662, 165.0556Harpagoside+−++\[[@CR10]\]P5681.455147.0450147.0452C~9~H~8~O~2~0.15147.0450Cinnamic acid+−+−\[[@CR10]\]P6298.429345.1014345.0980C~18~H~18~O~7~− 3.42345.10145,7,2′,4′-tetradihydroxy-8-methoyl-6-methyl-homoisoflavanone−−+−\[[@CR10]\]P74104.020359.1161359.1136C~19~H~20~O~7~− 2.47359.1161Ophiopogonanone E−++−\[[@CR10]\]P75105.884343.1215343.1187C~19~H~20~O~6~− 2.79343.12155-7-4′-trihydroxy-5′-methoxy-6,8-dimethyl hamoisoflavanone−−+−\[[@CR25]\]P77107.848327.0905327.0874C~18~H~16~O~6~− 3.09327.0905Ophiopogonone A−−+−\[[@CR10]\]P78110.065339.0898339.0874C~19~H~16~O~6~− 2.39339.0898Methylophiopogone A−++−\[[@CR10]\]P79110.853341.1059341.1031C~19~H~18~O~6~− 2.84206.0587, 178.0258Methylophiopogonanone A−−+−\[[@CR10]\]P80111.626327.1260327.1238C~19~H~20~O~5~− 2.20327.1260Methylophiopogone B−−+−\[[@CR10]\]a), t~R~, retention time; \*, \[M+HCOOH−H\]^−^, other, \[M−H\]^−^; P, plasma; U, urine; F, feces; B, bile. +, containing; −, notFig. 2EICs of rehmapicrogenin at m/z 183.1027, \[M−H\]^−^ in negative ion mode; **a** ZYD-containing and blank plasma sample; **b** ZYD-containing and blank feces sample; **c** ZYD-containing and blank bile sample; **d** ZYD-containing and blank urine sample; **e** ZYD

Identification of phenethylalchohol glycosides and phenylpropanoid glycosides {#Sec11}
-----------------------------------------------------------------------------

Totally 11 phenethylalchohol glycosides and phenylpropanoid glycosides were detected in vivo, and their structures usually included phenylethanol, phenylpropanoid, and glycoside units. Phenylethanol group often involved loss of neutral molecules like H~2~O, HCHO, and CH~3~OH. Phenylpropionic acid easily loses H~2~O due to the presence of hydroxyl and carboxyl groups. In another way, different phenylpropionic acid shows different typical fragments, such as ferulic acid (193, 178, 175, 149, 134), *p*-coumaric acid (163, 145, 119), cinnamic acid (147, 129, 103). In the case of angoroside C, the fragmentation pathway diagram was shown in Fig. [3](#Fig3){ref-type="fig"}. The quasi-molecular ion peak of angoroside C (783.2798 \[M−H\]^−^) could lose a series of residuals to generate ion peaks including 651.2173 \[M-Ara(132 Da)--H\]^−^, 633.2078 \[M-Ara-H~2~O--H\]^−^, *m/z* 607.2299 \[M-Feruloyl(176 Da)-H\]^−^, *m/z* 589.2192 \[M-Feruloyl-H~2~O--H\]^−^, *m/z* 637.2163 \[M-Rha(146 Da)--H\]^−^, *m/z* 475.1792 \[M-Ara-Feruloyl-H\]^--^, *m/z* 461.1707 \[M-Rha-Feruloyl-H\]^−^, *m/z* 443.1553 \[M-Rha-Feruloyl-H~2~O--H\]^--^, *m/z* 329.1226 \[M-Ara-Rha-Feruloyl-H\]^−^, *m/z* 311.1474 \[M-Rha-Ara-H~2~O--H\]^--^, and typical fragments where the residues further to break, such as feruloyl (175,134), 3-methylhydroxytyrosol (167), etc. Likewise, other compounds could produce similar fragments.Fig. 3Proposed fragmentation pathway diagram of angoroside C in the negative ion mode. Ara, arabinosyl; Rha, rhamnosyl; Glc, glucosyl; Feruloyl, Ferulic acid dehydration

Identification of iridoid glycosides {#Sec12}
------------------------------------

Iridoid glycosides are the main components of *Scrophulariae Radix* and dried *Rehmanniae Radix*, which have similar mother nuclei and mass spectral fragmentation pattern during cracking. These compounds generally produce precursor ions like \[M−H\]^−^, \[M+HCOOH--H\]^−^, \[M+Cl\]^−^, and \[2M−H\]^−^ in the negative ion mode. In the secondary ion mode, the glucosyl group (Glc, C~6~H~10~O~5~, 162 Da) were usually preferentially lost to expose iridoid mother nucleus. Subsequent loss of a series of H~2~O (18 Da) molecules occurred because of the presence of many hydroxyl groups (OH, 17 Da) in the mother nucleus. Fracture of the iridoid at enol-ether bonds was accompanied by the loss of acetaldehyde (CH~3~CHO, 44 Da), formaldehyde (HCHO, 30 Da), and H~2~O. Typical fragmentation pathway provided reliable information for the identification of iridoid glycosides. For instance, leonuride was the main iridoid glycosides in *Rehmanniae Radix*. The precursor ions were *m/z* 393.1503 \[M+HCOOH--H\]^−^, *m/z* 383.1210 \[M+Cl\]^−^, *m/z* 347.1439 \[M−H\]^−^, which produced *m/z* 185.0860 \[M-Glc-H\]^−^, *m/z* 167.0741 \[M-Glc-H~2~O--H\]^−^, *m/z* 149.0606 \[M-Glc-2H~2~O--H\]^−^, *m/z* 137.0203 \[M-Glc-HCHO--H\]^−^, *m/z* 123.0444 \[M-Glc-CH~3~CHO--H\]^−^. At the same time, the glucosyl residue also produced typical fragments such as *m/z* 161.0462, *m/z* 113.0227. In order to more intuitively display the fragmentation pathway of this type components, the proposed fragmentation pathways of leonuride in negative ion mode was exhibited in Fig. [4](#Fig4){ref-type="fig"}a.Fig. 4Proposed fragmentation pathways of **a** leonuride and **b** methylophiopogonanone A in the negative ion mode

Identification of homoisoflavones {#Sec13}
---------------------------------

Seven homoisoflavones were detected in T2DM rats. Homoisoflavones are a particular class of flavonoids, which are connected by methylene group (CH~2~) between B and C rings. Compound P79 was confirmed as methyl-ophiopogonanone A, the MS/MS spectrum and proposed fragmentation diagram were shown in Fig. [4](#Fig4){ref-type="fig"}b. P79 gave \[M−H\]^−^ at *m/z* 341.1051, in which fragmentation at *m/z* 206.0580 that originated from the initial loss of B-ring and CH~2~ to generate \[M-*B*-*ring*-CH~2~--H\]^−^. The ion at *m/z* 178.0629 was attributed to a loss of CO from *m/z* 206.0580. Besides, \[M−H\]^−^ ion just eliminated B-ring to produce the \[M-*B*-*ring*-H\]^−^ at *m/z* 219.1341. Analogously, the remaining six compounds were identified, respectively.

Identification of other compounds {#Sec14}
---------------------------------

Based on their exact molecular mass and MS/MS spectra, P14, P15, P20, P23, and P39 were temporarily identified as rhamnopyranosyl vanilloyl, darendoside B, rehmapicrogenin, rehmaionoside A/B, jiocarotenoside A1/A2, respectively.

Tentative characterization of the ZYD metabolites in T2DM rats {#Sec15}
--------------------------------------------------------------

Potential metabolic pathways of the ZYD components were determined by comparing data from public databases and relevant publications with the cleavage results of ZYD component mother nuclei. As a result, a total of 49 presumptive metabolites in plasma, feces, urine, and bile were preliminary illuminated. All metabolic components were listed in Table [2](#Tab2){ref-type="table"}.Table 2Identification of ZYD metabolic components in T2DM ratsPeak No.t~R~(min)Precursor ions (m/z)Error (mDa)FormulaFragment ions(m/z)IdentificationMetabolic typePUFBExpTheM112.985201.0776201.0768− 0.75C~9~H~14~O~5~201.0762, 157.0529, 139.0751HarpageninHydrolyzation+−**+**−M224.773377.1460377.1453− 0.68C~16~H~26~O~10~377.1460, 217.0938, 169.0841, 161.0465Dihydrogen methylcatalpolMethylation, hydrogenation+**+**−−M326.057263.0240263.0231− 0.90C~9~H~12~O~7~S263.0240, 183.0455, 165.0588, 121.0291Dehydrated harpagenin sulfateDehydration, sulfation−+−−M426.304153.0555153.05570.22C~8~H~10~O~3~153.0576, 123.0448, 135.0412, 121.0281HydroxytyrosolHydrolyzation+−+−M526.862583.1938583.20329.43C~27~H~36~O~14~583.2279, 195.0671, 151.0671, 179.0566, 161.0460, 149.0501Acetyl 6-O- dihydro-feruloyl harpagideHydrogenation, acetylation−−+−M629.227185.0819185.08190.13C~9~H~14~O~4~185.0819, 141.0891Deglucosylated leonurideDeglucosylation++−+M736.029225.0774225.0768− 0.55C~11~H~14~O~5~225.0801, 210.0793, 165.0556Methyl hydrated ferulic acidMethylation, hydration−−+−M831.271181.0506181.05060.03C~9~H~10~O~4~181.0513, 163.0398, 137.0514, 119.0498Hydrated *p*-coumaric acidHydration++++M935.171451.2234\*451.2185− 4.91C~19~H~34~O~9~451.2234, 225.0505, 179.0553, 161.0482Hydroxy rehmaionoside AHydroxylation−−+−M1036.81363.1109363.1085− 2.36C~18~H~20~O~8~363.1136, 345.1053, 183.0626, 179.0445, 165.0555, 139.0667Deglucosylated 8-O-caffeoyl-harpagideDeglucosylation−−+−M1137.114137.0602137.06080.6C~8~H~10~O~2~137.0602, 122.0397, 111.0424, 107.0455DeoxyhydroxytyrosolDeoxidation−−+−M1237.366489.1641489.1614− 2.74C~21~H~30~O~13~489.1641, 179.0363, 165.0542, 113.0249Didehydrated 8-O-caffeoyl harpagideDehydration−−−+M1337.895339.0709339.07221.26C~15~H~16~O~9~339.0709*p*-coumaric acid glucuronideGlucuronidation−−−+M1437.895181.0506181.05060.03C~9~H~10~O~4~181.0506, 163.0773, 137.0601,Dihydro-caffeic acidHydrogenation−++−M1539.276151.0405151.0405− 0.43C~8~H~8~O~3~151.0405, 123.0439, 107.0501Dehydrogen hydroxytyrosolDehydrogenation−++−M1639.401371.0993371.0984− 0.93C~16~H~20~O~10~371.0993, 195.0657, 177.0549, 193.0334, 175.0255, 113.0242Dihydro-ferulic acid glucuronideHydrogenation, glucuronidation++−−M1741.295369.0842369.0827− 1.48C~16~H~18~O~10~369.0842, 193.0504, 178.0272, 149.0599, 134.0369, 113.0232Ferulic acid glucuronideGlucuronidation++−+M1841.618233.0131233.0125− 0.57C~8~H~10~O~6~S233.0131, 153.0554, 135.0444, 123.0449, 121.0299, 109.0274Hydroxytyrosol sulfateSulfation−++−M1942.554341.0890341.0878− 1.19C~15~H~18~O~9~341.0890, 165.0556, 121.0657, 175.0233, 149.0598, 113.0236Dihydro-*p*-coumaric acid glucuronideHydrogenation, glucuronidation−+−−M2042.703357.0818357.08270.92C~15~H~18~O~10~357.0822, 339.0646, 175.0585, 131.0406Hydrated *p*-coumaric acid glucuronideGlucuronidation, hydration−−+−M2145.675181.0870181.08700.02C~10~H~14~O~3~181.0376, 137.0971, 122.0663, 121.0653Dehydro-rehmapicrogeninDehydrogenation+−+−M2245.826179.0350179.0350− 0.02C~9~H~8~O~4~179.0613, 135.0450, 161.4731,Caffeic acidHydrolyzation−++−M2347.591359.1361359.1348− 1.34C~16~H~24~O~9~359.1361, 183.1025, 139.1122, 113.0232Rehmapicrogenin glucuronideGlucuronidation−+−+M2447.813151.0398151.04010.27C~8~H~8~O~3~151.0398, 107.0500Dehydrogen hydroxytyrosolDehydrogenation−+−−M2548.821247.0288247.0282− 0.62C~9~H~12~O~6~S247.0288, 167.0711, 152.0474, 149.0285Methyl hydroxytyrosol sulfateMethylation, sulfation−+−−M2649.757385.1154385.1140− 1.38C~17~H~22~O~10~385.1154, 209.0821, 191.0689, 175.0120, 113.0244Dihydro-methyl ferulic acid glucuronideHydrogenation, methylation, glucuronidation−+−+M2750.395369.0827369.08270.02C~16~H~18~O~10~369.0842, 193.0504, 178.0272, 149.0599, 134.0369, 113.0232Ferulic acid glucuronideGlucuronidation−−−+M2854.181275.0239275.0231− 0.8C~10~H~12~O~7~S275.0239, 195.0662, 177.0558, 151.0761, 136.0524, 121.0293Dihydro-ferulic acid sulfateHydrogenation, sulfation−+−−M2954.078195.0667195.0663− 0.42C~10~H~12~O~4~195.0676, 177.0570, 136.0524Dihydro-ferulic acidHydrogenation+++−M3055.035165.0556165.05570.12C~9~H~10~O~3~165.0559, 147.0427, 129.0326, 121.0655Hydrated cinnamic acidHydration−−++M3155.744233.0139233.0125− 1.37C~8~H~10~O~6~S233.0131, 153.0554, 135.0444, 123.0449Hydroxytyrosol sulfateSulfation−−+−M3255.195331.1208331.1187− 2.09C~18~H~20~O~6~331.1222, 313.1108, 287.0830, 165.0553, 147.0440, 103.0543Deglucosylated harpagosideDeglucosylation−−+−M3356.101521.1820521.1664− 12.05C~25~H~30~O~12~521.1785, 503.1661, 183.0665, 157.0509, 193.0404, 113.0247Dehydrated harpa-gide glucuronideDehydration, glucuronidation−−+−M3456.427245.0133245.0125− 0.77C~9~H~10~O~6~S245.0133, 165.0554, 147.0432, 121.0657Dihydro-*p*-coumaric acid sulfateHydrogenation, sulfation−+−−M3558.309209.0822209.0819− 0.27C~11~H~14~O~4~209.0813, 191.0713, 165.0926, 149.0616Dihydro-methyl ferulic acidHydrogenation, methylation+−+−M3658.362273.0083273.0074− 0.85C~10~H~10~O~7~S273.0083, 193.0503, 178.0268, 134.0369Ferulic acid sulfateSulfation−+−−M3759.756625.2194625.2194− 5.61C~29~H~38~O~15~625.2194, 461.1695, 315.1104, 181.0510, 163.0407, 153.0538Dihydro-acteosideHydrogenation−−+−M3860.258217.1088217.1081− 0.65C~10~H~18~O~5~217.1087, 199.0936, 186.2198, 171.1025, 155.1062, 153.0895Dihydro-methyl harpageninHydrogenation, methylation−−+−M3961.965135.0449135.04520.25C~8~H~8~O~2~135.0449, 123.0065, 107.0468, 100.9257Dehydrated hydroxytyrosolDehydration+−+−M4063.176361.1518361.1504− 1.39C~16~H~26~O~9~361.2317, 185.1180, 141.1279, 113.0242Dihydrogen rehmapicrogenin glucuronideHydrogenation, glucuronidation−+−−M4164.035247.0294247.0282− 1.22C~9~H~12~O~6~S247.0537, 167.0706, 152.0476Methyl hydroxytyrosol sulfateMethylation, sulfation−−+−M4266.026377.1471377.1453− 1.78C~16~H~26~O~10~377.1471, 201.1129, 183.1002, 165.0567, 175.0242, 113.0242Harpagenin glucuronideGlucuronidation−+−+M4370.428637.2199637.2138− 6.11C~30~H~38~O~15~637.2155, 461.1706, 193.0512, 135.0407Methyl acteosideMethylation−−+−M4472.673275.0246275.0231− 1.50C~10~H~12~O~7~S275.0240, 195.0665, 177.0575, 151.0772Hydrated ferulic acid sulfateHydration, sulfation+−+−M4572.935245.0135245.0125− 0.97C~9~H~10~O~6~S245.0135, 165.0666, 147.0549, 121.0355Dihydro-*p*-coumaric acid sulfateHydrogenation, sulfation−−+−M4678.821273.0081273.0074− 0.65C~10~H~10~O~7~S273.0090, 193.0506, 178.0271, 134.0372Ferulic acid sulfateSulfation+−−+M4778.166149.0609149.0608− 0.10C~9~H~10~O~2~149.0609, 107.0480, 105.0703Dihydro-cinnamic acidHydrogenation−−+−M4879.350583.2092583.2032− 5.97C~27~H~36~O~14~583.2100, 193.0525, 149.0439, 201.1145, 183.0656, 165.0568Acetyl-6-O-dihydro-feruloyl harpagideHydrogenation, acetylation−−+−M4974.738315.1270315.12972.67C~14~H~20~O~8~315.1278, 297.1136, 161.0582, 135.0442Hydroxytyrosol glucosylateHydrolyzation−−+−a): P, plasma; U, urine; F, feces; B, bile. +, containing; −, not

Identification of iridoid glycoside-related metabolites {#Sec16}
-------------------------------------------------------

Totally 12 metabolites of the iridoids were initially identified, most of which were derived from the metabolism of harpagide and its derivatives. Harpagide and its derivatives easily lose a glycosyl group and are converted to harpagenin by hydrolases. M1 displayed \[M−H\]^−^ at *m/z* 201.1129, which typical product ions were basically consistent with the above description of harpagide. M42 showed \[M−H\]^−^ at *m/z* 377.1471, and the fragment ion at *m/z* 201.1129 was yielded obviously by the loss of a GluA group (176 Da). Simultaneously, the deglucose products of some other iridoid glycosides were also found. M6 displayed \[M−H\]^−^ at *m/z* 185.0819, a neutral loss of 162 Da (Glc) comparing with leonuride, indicating it was deglucosylated leonuride. M32 exhibited \[M−H\]^−^ at *m/z* 331.1208. Comparing to harpagoside, the metabolite underwent a loss of glucosyl group. Possible metabolic pathways of harpagide and leonuride were shown in Fig. [5](#Fig5){ref-type="fig"}a, b.Fig. 5Possible metabolic pathways of major iridoid glycosides in T2DM rats. **a** Harpagide; **b** Leonuride

Identification of phenylpropanoid-related metabolites {#Sec17}
-----------------------------------------------------

A total of 23 constituents were initially identified as generating from the metabolism of phenylpropanoid-related compounds. The metabolic pathways were shown in Fig. [6](#Fig6){ref-type="fig"}a--c. \[M−H\]^--^ ions, M19 at *m/z* 341.0890 and M34 at *m/z* 245.0133, had formed by the addition of 176 Da (GluA, C~6~H~8~O~7~) and 80 Da (SO~3~), respectively, to *m/z* 165.0554. Both had neutral losses of H~2~O and CO~2~ (44 Da). The metabolic profile was consistent with *p*-coumaric acid, indicating that the two metabolites were the glucuronidation and sulfonation products of dihydro *p*-coumaric acid. At the same time, the demethylation and hydrogenation products of ferulic acid were also observed. The demethylated product M22, called caffeic acid, neutral losing CO~2~ to produce abundant fragments of *m/z* 135.0450. The neutral loss of hydrogenated product M29 was the same as that of ferulic acid, including the loss of H~2~O to produce *m/z* 177.0570, and the loss of CO~2~ and methyl group (CH~3~, 15 Da) to produce typical debris *m/z* 136.0524, etc. The other 19 metabolites were identified in a similar manner.Fig. 6Possible metabolic pathways for major ZYD compounds in T2DM rats. **a** ferulic acid; **b** cinnamic acid; **c***p*-coumaric acid; and **d** Hydroxytyrosol

Identification of hydroxytyrosol-related metabolites {#Sec18}
----------------------------------------------------

Hydroxytyrosol (HT) was mainly derived from phenylethanoid glycosides, which was produced by hydrolysis and formed different metabolites through various metabolic pathways in vivo. In this study, ten HT-related metabolites were identified in vivo, and the specific metabolic pathways were shown in Fig. [6](#Fig6){ref-type="fig"}d. M15 showed \[M−H\]^--^ at *m/z* 151.0405, the loss of 2 Da (2H) from HT, suggesting that the metabolite was generated from the dehydrogenation of HT. Moreover, M18 and M31 both yielded \[M−H\]^−^ at *m/z* 233.0139, linkage of an SO~3~ group separately, suggesting it to be hydroxytyrosol sulfated. Furthermore, both M25 and M41 showed \[M−H\]^−^ at *m/z* 247.0288, the addition of methyl to M18 and M31, respectively.

Identification of metabolic components of other compounds {#Sec19}
---------------------------------------------------------

Analysis of the fragmentation pattern of rehmaionoside A found that M9 showed \[M+HCOOH-H\]^--^ at *m/z* 451.2234, an addition of 16 Da to \[rehmaionoside A-H\]^−^, suggesting that M9 was tentatively identified as hydroxyrehmaionoside A. The product ion *m/z* 243.1105, and 225.0782 were losses of glucosyl group and water from M9. The product ions of M23 included *m/z* 183.1025, *m/z* 139.1122, *m/z* 175.0294, and *m/z* 113.0232. *m/z* 183.1025, and *m/z* 139.1122 were product ions of P20 and *m/z* 175.0294, *m/z* 113.0232 were the characteristic fragments of glucuronic acid. M23 was thus initially identified as a glucuronic acid-binding product of rehmapicrogenin. Also, the dehydrogenation product M21 (*m/z* 181.087) of rehmapicrogenin, and the hydrogenation product M40 (*m/z* 361.1518) of M23 were observed. The above fragmentation regularity was consistent with rehmapicrogenin.

Distribution of ZYD metabolites in T2DM rats {#Sec20}
--------------------------------------------

According to the distribution of ZYD metabolites in T2DM rats, Fourteen metabolites were found in plasma samples, 23 in urine, 33 in feces, and 11 in bile, which all have been identified and the details were listed in Table [2](#Tab2){ref-type="table"}. Harpagoside, an iridoid glycoside, was the primary bioactive constituent of ZYD, which was detected in plasma, bile and feces samples of T2DM rats and its possible metabolites could be found in all bio-samples. For example, deglucosylation of harpagoside was observed in feces due to the transformation of harpagoside by glycoside hydrolase in the gut. Besides, glucuronic conjugates of *p*-coumaric acid, harpagenin, ferulic acid, and rehmapicrogenin were detected in bile, which was consistent with the glucuronic conjugates as the primarily metabolites in bile excretion. Meanwhile, *p*-coumaric acid was found in plasma, urine, and feces, but not in bile. It was likely that *p*-coumaric acid was metabolized to a glucuronic conjugate in the liver and then excreted into the duodenum via the bile duct and regenerated the prototype by a glucuronidase, and some of them were reabsorbed into the liver through the enterohepatic circulation.

Discussion {#Sec21}
==========

According to the results of the pre-experiment, there was no significant difference between the previously established method and the current method in the HPLC optimization process \[[@CR10]\]. Hence, the previous performance was used for the next experiment. Besides, the negative ion mode was chosen for further analysis because most of the compounds in ZYD contain functional groups such as hydroxyl, carboxyl, etc., and most components can be detected in the negative ion mode.

Sufficient detection level was the premise of instrument analysis \[[@CR26]\]. The low concentrations of TCM components in vivo and possibly substantial interference by the matrix effect posed significant challenges for the analysis in vivo \[[@CR27]\]. Samples handling has become the essential part of biological sample analysis, so it was of considerable significance to choose the appropriate pretreatment method. In the current research, dialysis, protein precipitation (PPT), solid phase extraction (SPE), immunoaffinity extraction, and other methods were widely used for the biological samples pretreatment. Among them, the PPT shows the advantages of simplicity, rapidity, and convenience, and it has been widely used in the qualitative analysis of TCM in vivo \[[@CR28]\]. So PPT was the preferred method for this experiment.

The effectiveness of TCM for disease prevention and treatment depends on the active ingredients contained in TCM \[[@CR29]\]. The absorption of a drug is a prerequisite for its pharmacological activity within the body. Therefore, it was assumed that the absorbable component might be an active ingredient, and that the disease condition might have some impacts on the absorption process \[[@CR30]\]. Diabetes may reduce the expression and function of P-glycoprotein (P-gp) in the intestine \[[@CR31]\]. When the intestinal P-gp activity is inhibited, the absorption of some drugs will be enhanced in the intestine \[[@CR32]\]. A previous study found that the plasma concentrations of catalpol and harpagide in diabetes-model rats were increased compared with normal rats, and that the clearance rate was slower \[[@CR11]\]. Diabetes also changes the experesion of cytochrome P450 enzymes, including CYP3A4, CYP2E1, CYP2C9, and CYP2D4 participate in phase I drug metabolism \[[@CR33]--[@CR35]\]. Catalpol has been shown to effect the activity of CYP3A4, CYP2E1 and CYP2C9 that resulted in pharmacokinetic interactions of coadministered drugs \[[@CR36]\]. It is possible that differences in the pharmacokinetics of ZYD compounds in diabetic and normal rats may be caused by disease-associated changes in some functional enzymes.

Some of the prototype and metabolic components identified in ZYD have had pharmacological effects in the treatment of T2DM in animal models and in cell lines. Harpagoside in ZYD could activate the PPAR-γ pathway in 3T3-L1 adipocytes to regulate lipid and glucose metabolism similar to the hypoglycemic effects of thiazolidinedione \[[@CR37], [@CR38]\]. *p*-Coumaric acid was shown to promote glucose uptake and utilization by activating the AMPK pathway and upregulating GLUT2 expression \[[@CR39], [@CR40]\]. Ferulic acid was reported to promote glucose uptake by activating PI3K-Akt pathway and upregulating the expression of GLUT4. It has also been found to promote glycogen synthesis and inhibit gluconeogenesis by downregulating the expression of PEPCK, G6PC and upregulating glucokinase expression \[[@CR41]--[@CR44]\]. In addition, Ferulic acid was also found to increase intracellular Ca^2+^ to promote insulin secretion \[[@CR44], [@CR45]\]. Among metabolites, caffeic acid was shown to increase insulin sensitivity in HepG2 cells, reduce hepatic glucose output, enhance glucose uptake, promote insulin secretion, and increase antioxidant activity in adipocytes \[[@CR45]--[@CR48]\]. Our previous study showed that ZYD had hypoglycemic activity, improved dyslipidemia, and promoted pancreatic islet-cell function in T2DM model rats \[[@CR12]\]. Knowing which of the chemical constituents of ZYD presented in vivo is essential for further investigation of the material basis and mechanism of ZYD in the treatment of T2DM.

Conclusions {#Sec22}
===========

ZYD is increasingly used for the treatment of T2DM. However there have been few reports on the component analysis of ZYD in vivo and even fewer in the pathological state of T2DM. This study identified and tentatively characterized previously undetected ZYD ingredients and was the first to systematically analyze the metabolism of ZYD ingredients in T2DM rats. As a consequence, thirty-six prototype components and 49 metabolites were presumed and characterized in vivo, and the proposed fragmentation pathways and possible metabolic behaviors of the main types of compounds were analyzed. In summary, this study added to the understanding of the chemical profile of ZYD and its metabolism information in T2DM rats. It provided essential data for the detailed pharmacokinetic study and pharmacodynamic material basis of ZYD in T2DM. Meanwhile, the study methods are applicable to the study of the metabolism of other TCM prescriptions.

Supplementary information
=========================

 {#Sec23}

**Additional file 1: Table S1.** Compounds information of ZYD by HPLC-ESI-Q-TOF MS/MS.

Ara

:   Arabinosyl group

FBG

:   Fasting blood glucose

Glc

:   Glucosyl group

GluA

:   Glucuronic acid group

HT

:   Hydroxytyrosol

PPT

:   Protein precipitation

Rha

:   Rhamnosyl group

T2DM

:   Type 2 diabetes mellitus

TCM

:   Traditional Chinese medicine

STZ

:   Streptozotocin

ZYD

:   Zengye decoction
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